Panacea Biotec Complete Financial Statements
In FY2025, Panacea Biotec (PANACEABIO) reported revenue ₹150 Cr, net profit ₹-14 Cr and EPS ₹-2.27, with a net profit margin of -9.3% and ROE of -1.7%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Panacea Biotec stock price NSE.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
PANACEABIO Revenue, Net Profit & EBITDA — Year-on-Year Growth
PANACEABIO YoY (Sept 2024 vs Sept 2025) — revenue -3.2%, net profit -380.0%, EBITDA -164.3%, expenses +13.6%. Review PANACEABIO P/E comparison to evaluate earnings-based valuation against sector peers.
PANACEABIO Income Statement — Revenue, EBITDA & Net Profit
Panacea Biotec revenue ₹150 Cr, EBITDA ₹-9 Cr, net profit ₹-14 Cr, EPS ₹-2.27 (2025) — net profit margin -9.3%. Explore PANACEABIO Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150 | 169 | 184 | 170 | 155 | 150 | 122 | 170 | 149 | 163 | 163 | 159 | 143 | 1,821 | 151 | 157 | 234 | 173 | 136 | 158 | 184 | 144 | 134 | 144 | 129 | 485 | 131 | 171 | 122 | 123 | 114 |
| Expenses | 159 | 159 | 168 | 153 | 140 | 143 | 130 | 156 | 147 | 135 | 140 | 151 | 109 | 171 | 191 | 124 | 226 | 167 | 134 | 144 | 144 | 150 | 111 | 127 | 149 | 258 | 104 | 132 | 179 | 116 | 87 |
| EBITDA | -9 | 9 | 16 | 17 | 14 | 8 | -8 | 14 | 2 | 29 | 24 | 8 | 34 | 1,650 | -40 | 33 | 8 | 6 | 2 | 14 | 40 | -6 | 23 | 17 | -20 | 228 | 27 | 39 | -57 | 7 | 27 |
| Operating Profit Margin % | -13.00% | -20.00% | -1.00% | 7.00% | 5.00% | -4.00% | -12.00% | 5.00% | -2.00% | -4.00% | -8.00% | 0.00% | -4.00% | -21.00% | -72.00% | -8.00% | 3.00% | 1.00% | -1.00% | 8.00% | 21.00% | -19.00% | 16.00% | 11.00% | -19.00% | -110.00% | 17.00% | 21.00% | -48.00% | -17.00% | 21.00% |
| Depreciation | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 10 | 11 | 10 | 10 | 11 | 12 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 13 | 11 | 11 | 14 | 14 | 52 |
| Interest | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 31 | 1 | 1 | 50 | 47 | 48 | 52 | 48 | 45 | 45 | 46 | 42 | 26 | 41 | 47 | 29 | 25 | -14 |
| Profit Before Tax | -19 | 0 | 7 | 7 | 5 | -2 | -17 | 4 | -8 | 18 | 13 | -2 | 23 | 1,608 | -51 | 22 | -53 | -53 | -57 | -49 | -19 | -61 | -34 | -40 | -73 | 189 | -25 | -19 | -99 | -33 | -11 |
| Tax | -5 | 2 | 3 | 3 | 0 | 0 | -1 | 0 | 1 | 31 | 2 | 1 | 8 | 371 | 5 | 3 | 0 | 2 | 0 | 0 | 0 | 9 | 0 | 0 | 2 | 3 | 3 | 2 | -2 | 3 | 5 |
| Net Profit | -14 | -2 | 4 | 4 | 5 | -2 | -16 | 4 | -8 | -13 | 11 | -2 | 16 | 1,238 | -56 | 19 | -53 | -54 | -57 | -49 | -19 | -70 | -34 | -40 | -75 | 186 | -28 | -21 | -97 | -35 | -16 |
| Earnings Per Share (₹) | -2.27 | -0.31 | 0.66 | 0.65 | 0.77 | -0.23 | -2.59 | 0.74 | -1.35 | -2.03 | 1.79 | -0.37 | 2.56 | 202.03 | -9.17 | 3.16 | -8.65 | -8.84 | -9.36 | -8.03 | -3.16 | -11.38 | -5.58 | -6.54 | -12.25 | 30.35 | -4.62 | -3.48 | -15.83 | -5.75 | -2.60 |
PANACEABIO Balance Sheet — Assets, Liabilities & Shareholders' Equity
PANACEABIO total assets ₹1,290 Cr, total equity ₹831 Cr, total liabilities ₹ Cr (2025) — ROE -1.7%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 1,290 | 1,241 | 1,271 | 1,759 | 1,178 | 1,390 | 1,376 | 1,608 | 1,800 | 1,854 | 1,931 |
| Current Assets | 545 | 485 | 562 | 951 | 511 | 683 | 508 | 560 | 533 | 549 | 526 |
| Fixed Assets | 567 | 582 | 600 | 622 | 609 | 657 | 806 | 949 | 1,001 | 1,071 | 1,144 |
| Capital Work in Progress | 128 | 102 | 42 | 17 | 34 | 24 | 23 | 40 | 30 | 161 | 156 |
| Investments | 3 | 40 | 14 | 5 | 0 | 6 | 5 | 7 | 7 | 4 | 5 |
| Other Assets | 592 | 517 | 615 | 1,115 | 534 | 703 | 542 | 611 | 761 | 619 | 626 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 92 | 94 | 101 | 109 | 960 | 739 | 90 | 611 | 846 | 930 | 750 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 831 | 838 | 840 | 874 | -232 | 196 | 347 | 306 | 366 | 450 | 475 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 22 | 22 |
| Reserves & Surplus | 807 | 814 | 816 | 849 | -257 | 139 | 335 | 293 | 340 | 426 | 449 |
PANACEABIO Cash Flow Statement — Operating, Investing & Financing
Panacea Biotec operating cash flow ₹-27 Cr, investing ₹65 Cr, financing ₹-3 Cr, net cash flow ₹35 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -27 | 0 | -423 | -108 | 107 | -31 | 105 | 118 | 131 | 91 | 37 |
| Investing Activities | 65 | 10 | 430 | 1,283 | -48 | -35 | -6 | 55 | -26 | 17 | -37 |
| Financing Activities | -3 | -3 | -18 | -1,176 | -47 | 91 | -101 | -164 | -107 | -117 | -1 |
| Net Cash Flow | 35 | 7 | -11 | -2 | 12 | 26 | -2 | 9 | -2 | -10 | -1 |